HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

World’s First Phase 3 Clinical Trial of China’s COVID-19 Inactivated Vaccine Begins in UAE

By HospiMedica International staff writers
Posted on 20 Jul 2020
Print article
Image: World’s First Phase 3 Clinical Trial of China’s COVID-19 Inactivated Vaccine Begins in UAE) (Photo courtesy of AETOSWire)
Image: World’s First Phase 3 Clinical Trial of China’s COVID-19 Inactivated Vaccine Begins in UAE) (Photo courtesy of AETOSWire)
The first WHO enlisted global clinical Phase 3 trial of China’s inactivated vaccine to combat COVID-19 has begun in Abu Dhabi, UAE.

The inactivated COVID-19 vaccine has been developed by the Wuhan Institute of Biological Products under the China National Biotec Group (CNBG) affiliated to the China National Pharmaceutical Group Co., Ltd. (Sinopharm Beijing, China). The world's first inactivated COVID-19 vaccine produced antibodies in every participant in Phase 1/2 clinical trials. Sheikh Abdullah bin Mohammed Al Hamed, Chairman of the Department of Health, Abu Dhabi, was the first in the world to commence the trial of a Phase 3 inactivated vaccine for COVID-19. The UAE was selected to conduct the trials as the nation is home to over 200 nationalities, allowing for robust research across multiple ethnicities and increasing its feasibility for global application.

The trials are as a result of a cooperation partnership between G42 Healthcare and Sinopharm CNBG, the world’s sixth largest vaccine manufacturer. UAE Health Authorities have issued a permit for up to 15,000 volunteers to participate in the trials while G42 Healthcare and Abu Dhabi Health Services (SEHA) are working towards achieving a minimum of 5,000 participants for the trials being supervised by the Department of Health Abu Dhabi and SEHA following international guidelines stipulated by WHO and USFDA.

“Our participation in this trial enables us to make a major contribution in the global fight to combat the COVID-19 pandemic. We are proud to facilitate the testing process that if successful leads to the manufacture of a vaccine,” said Dr. Nawal Ahmed Alkaabi, Chairperson of the UAE National COVID-19 Clinical Management Committee.

“We are enormously proud to partner with Sinopharm CNBG in this groundbreaking phase III clinical trial. Using our AI solutions, super-computer, advanced diagnostics solutions for COVID-19, and G42 Healthcare will be responsible for running clinical operations for these trials,” said Ashish Koshy, CEO of G42 Healthcare.

“The UAE is a nation of innovation and tolerance, home to individuals from every part of the world and ethnic background. We will work closely with our partner G42 Healthcare, with the support of the Abu Dhabi health authorities to complete these clinical trials successfully and make this vaccine available to people in need worldwide,” added Jingjin Zhu, President, Biological products, Sinopharm CNBG.

Related Links:
China National Pharmaceutical Group Co., Ltd.

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
Disposable Protective Suit For Medical Use
Disposable Protective Suit For Medical Use
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
X-Ray QA Meter
Piranha CT

Print article

Channels

Critical Care

view channel
Image: The new risk assessment tool determines patient-specific risks of developing unfavorable outcomes with heart failure (Photo courtesy of 123RF)

Powerful AI Risk Assessment Tool Predicts Outcomes in Heart Failure Patients

Heart failure is a serious condition where the heart cannot pump sufficient blood to meet the body's needs, leading to symptoms like fatigue, weakness, and swelling in the legs and feet, and it can ultimately... Read more

Surgical Techniques

view channel
Image: The multi-sensing device can be implanted into blood vessels to help physicians deliver timely treatment (Photo courtesy of IIT)

Miniaturized Implantable Multi-Sensors Device to Monitor Vessels Health

Researchers have embarked on a project to develop a multi-sensing device that can be implanted into blood vessels like peripheral veins or arteries to monitor a range of bodily parameters and overall health status.... Read more

Patient Care

view channel
Image: The portable, handheld BeamClean technology inactivates pathogens on commonly touched surfaces in seconds (Photo courtesy of Freestyle Partners)

First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds

Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The Quantra Hemostasis System has received US FDA special 510(k) clearance for use with its Quantra QStat Cartridge (Photo courtesy of HemoSonics)

Critical Bleeding Management System to Help Hospitals Further Standardize Viscoelastic Testing

Surgical procedures are often accompanied by significant blood loss and the subsequent high likelihood of the need for allogeneic blood transfusions. These transfusions, while critical, are linked to various... Read more